Vor Biopharma (VOR) Leases (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Leases data on file, last reported at $2.8 million in Q1 2026.

• Quarterly Leases fell 91.61% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 91.61% YoY) and the FY2025 annual result came in at $2.9 million, down 91.61% from the prior year.
• Leases slipped to $2.8 million in Q1 2026 per VOR's latest filing, from $2.9 million in the prior quarter.
• Across five years, Leases topped out at $46.1 million in Q2 2022 and bottomed at $24000.0 in Q2 2025.
• The 5-year median for Leases is $37.6 million (2024), against an average of $30.3 million.
• The widest annual swing landed in 2022, when Leases soared 183.62%; it then tumbled 99.94% in 2025.
• Tracing VOR's Leases over 5 years: stood at $44.4 million in 2022, then declined by 9.89% to $40.0 million in 2023, then slipped by 12.59% to $35.0 million in 2024, then plunged by 91.61% to $2.9 million in 2025, then declined by 3.71% to $2.8 million in 2026.
• Per Business Quant, the three latest VOR Leases figures stand at $2.8 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025).

Peer Comparison